Top

Published in:

01-10-2006 | Article

Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice

Authors: H. Makino, M. Mukoyama, K. Mori, T. Suganami, M. Kasahara, K. Yahata, T. Nagae, H. Yokoi, K. Sawai, Y. Ogawa, S. Suga, Y. Yoshimasa, A. Sugawara, I. Tanaka, K. Nakao

Published in: Diabetologia | Issue 10/2006

Abstract

Aims/hypothesis

Brain natriuretic peptide (BNP) is a potent vasorelaxing and natriuretic peptide that is secreted from the heart and has cardioprotective properties. We have previously generated hypotensive transgenic mice (BNP-Tg mice) that overproduce BNP in the liver, which is released into the circulation. Using this animal model, we successfully demonstrated the amelioration of renal injury after renal ablation and in proliferative glomerulonephritis. Glomerular hyperfiltration is an early haemodynamic derangement, representing one of the key mechanisms of the pathogenesis of diabetic nephropathy. Based on the suggested involvement of increased endogenous natriuretic peptides, the aim of this study was to investigate their role in the development and progression of diabetic nephropathy.

Materials and methods

We evaluated the progression of renal injury and fibrogenesis in BNP-Tg mice with diabetes induced by streptozotocin. We also investigated the effect of BNP on high glucose-induced signalling abnormalities in mesangial cells.

Results

After induction of diabetes, control mice exhibited progressively increased urinary albumin excretion with impaired renal function, whereas these changes were significantly ameliorated in BNP-Tg mice. Notably, diabetic BNP-Tg mice revealed minimal mesangial fibrogenesis with virtually no glomerular hypertrophy. Glomerular upregulation of extracellular signal-regulated kinase, TGF-β and extracellular matrix proteins was also significantly inhibited in diabetic BNP-Tg mice. In cultured mesangial cells, activation of the above cascade under high glucose was abrogated by the addition of BNP.

Conclusions/interpretation

Chronic excess of BNP prevents glomerular injury in the setting of diabetes, suggesting that renoprotective effects of natriuretic peptides may be therapeutically applicable in preventing the progression of diabetic nephropathy.

Remuzzi G, Schieppati A, Ruggenenti P (2002) Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145–1151PubMedCrossRef

Parving HH, Mauer M, Ritz E (2004) Diabetic nephropathy. In: Brenner BM (ed). The Kidney. 7th Edition. WB Saunders, Philadelphia, pp 1777–1818

Ziyadeh FN, Sharma K (2003) Overview: combating diabetic nephropathy. J Am Soc Nephrol 14:1355–1357PubMedCrossRef

The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef

Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer SM (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69–75PubMedCrossRef

UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713

Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef

Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef

Nakao K, Ogawa Y, Suga S, Imura H (1992) Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens 10:907–912PubMed

10.

Lopez MJ, Wong SK, Kishimoto I et al (1995) Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378:65–68PubMedCrossRef

11.

Nakao K, Itoh H, Saito Y, Mukoyama M, Ogawa Y (1996) The natriuretic peptide family. Curr Opin Nephrol Hypertens 5:4–11PubMedCrossRef

12.

Mukoyama M, Nakao K, Hosoda K et al (1991) Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402–1412PubMed

13.

Drewett JG, Garbers DL (1994) The family of guanylyl cyclase receptors and their ligands. Endocr Rev 15:135–162PubMedCrossRef

14.

Trevisan R, Fioretto P, Semplicini A et al (1990) Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes 39:289–298PubMedCrossRef

15.

Yano Y, Katsuki A, Gabazza EC et al (1999) Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 84:2353–2356PubMedCrossRef

16.

Zietse R, Weimar W, Schalekamp MA (1997) Atrial natriuretic peptide in diabetic nephropathy. Kidney Int 60:S33–S41

17.

Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH (2005) Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 48:149–155PubMedCrossRef

18.

Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM (1987) Elevated plasma atrial natriuretic peptide levels in diabetic rats: potential mediator of hyperfiltration. J Clin Invest 80:670–674PubMed

19.

Zhang PL, Mackenzie HS, Troy JL, Brenner BM (1994) Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol 4:1564–1570PubMed

20.

Nakamoto M, Shapiro JI, Shanley PF, Chan L, Schrier RW (1987) In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. J Clin Invest 80:698–705PubMed

21.

Allgren RL, Marbury TC, Rahman SN et al (1997) Anaritide in acute tubular necrosis. N Engl J Med 336:828–834PubMedCrossRef

22.

Ogawa Y, Itoh H, Tamura N et al (1994) Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 93:1911–1921PubMed

23.

Kasahara M, Mukoyama M, Sugawara A et al (2000) Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 11:1691–1701PubMed

24.

Suganami T, Mukoyama M, Sugawara A et al (2001) Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 12:2652–2663PubMed

25.

Makino H, Tanaka I, Mukoyama M et al (2002) Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP₁-selective antagonist. J Am Soc Nephrol 13:1757–1765PubMedCrossRef

26.

Ishibashi R, Tanaka I, Kotani M et al (1999) Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 56:589–600PubMedCrossRef

27.

Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814–1818PubMedCrossRef

28.

Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020PubMedCrossRef

29.

Tomlinson DR (1999) Mitogen-activated protein kinase as glucose transducers for diabetic complications. Diabetologia 42:1271–1281PubMedCrossRef

30.

Isono M, De La Cruz MC, Chen S, Hong SW, Ziyadeh FN (2000) Extracellular signal-regulated kinase mediates stimulation of TGF-β1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 11:2222–2230PubMed

31.

Toyoda M, Suzuki D, Honma M et al (2004) High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 66:1107–1114PubMedCrossRef

32.

Fujihara CK, Padiha RM, Zats R (1992) Glomerular abnormalities in long-term experimental diabetes: role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes 41:286–293PubMedCrossRef

33.

Pedersen MM, Christiansen JS, Pedersen EB, Mogensen CE (1992) Determinants of intra-individual variation in kidney function in normoalbuminuric insulin-dependent diabetic patients: importance of atrial natriuretic peptide and glycaemic control. Clin Sci 83:445–451PubMed

34.

Jacobs EMG, Vervoort G, Branten AJW, Klasen I, Smits P, Wetzels JFM (1999) Atrial natriuretic peptide increases albuminuria in type 1 diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 29:109–115PubMedCrossRef

35.

Huang C, Kim Y, Caramori ML et al (2002) Cellular basis of diabetic nephropathy: II. The transforming growth factor-β system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 51:3577–3581PubMedCrossRef

36.

Taal MW, Nenov VD, Wong W et al (2001) Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051–2059PubMed

37.

Sugimoto T, Haneda M, Togawa M et al (1996) Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells. J Biol Chem 271:544–547PubMedCrossRef

38.

Koya D, Haneda M, Nakagawa H et al (2000) Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439–447PubMed

39.

Ishii H, Jirousek MR, Koya D et al (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728–731PubMedCrossRef

40.

Kriz W, LeHir M (2005) Pathways to nephron loss starting from glomerular diseases: insights from animal models. Kidney Int 67:404–419PubMedCrossRef

41.

Koshikawa M, Mukoyama M, Mori K et al (2005) Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16:2690–2701PubMedCrossRef

42.

Pagtalunan ME, Miller PL, Jumping-Eagle S et al (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342–348PubMedCrossRef

43.

Lewko B, Endlich N, Kriz W, Stepinski J, Endlich K (2004) C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int 66:1001–1008PubMedCrossRef

44.

Higashiura K, Ura N, Takada T et al (2000) The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 13:290–297PubMedCrossRef

45.

Shiuchi T, Iwai M, Li HS et al (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43:1003–1010PubMedCrossRef

46.

Lindholm LH, Ibsen H, Borch-Johnsen K et al (2002) Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20:1879–1886PubMedCrossRef

47.

Suda M, Ogawa Y, Tanaka K et al (1998) Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc Natl Acad Sci USA 95:2337–2342PubMedCrossRef

48.

Yasoda A, Komatsu Y, Chusho H et al (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10:80–86PubMedCrossRef

Title: Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice
Authors: H. Makino
M. Mukoyama
K. Mori
T. Suganami
M. Kasahara
K. Yahata
T. Nagae
H. Yokoi
K. Sawai
Y. Ogawa
S. Suga
Y. Yoshimasa
A. Sugawara
I. Tanaka
K. Nakao
Publication date: 01-10-2006
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 10/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0352-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 10/2006

Hyperinsulinism in mice with heterozygous loss of KATP channels

Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction

Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4

Altered cerebral regulation in type 2 diabetic patients with cardiac autonomic neuropathy

Genotype-by-sex interaction in the aetiology of type 2 diabetes mellitus: support for sex-specific quantitative trait loci in Hypertension Genetic Epidemiology Network participants

The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials